Skip to Content
Merck
All Photos(1)

Key Documents

View All Documentation

O1014

Sigma-Aldrich

Octreotide

≥98% (HPLC)

Synonym(s):

SMS 201-995

Sign Into View Organizational & Contract Pricing
All Photos(1)

About This Item

Empirical Formula (Hill Notation):
C49H66N10O10S2
CAS Number:
83150-76-9
Molecular Weight:
1019.24
MDL number:
MFCD00871400
UNSPSC Code:
12352200
PubChem Substance ID:
329818892
NACRES:
NA.32

Quality Level

200

Assay

≥98% (HPLC)

solubility

H2O: soluble

storage temp.

−20°C

SMILES string

C[C@@H](O)[C@@H](CO)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@H](N)Cc2ccccc2)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@H](Cc4c[nH]c5ccccc45)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1

InChI

1S/C49H66N10O10S2/c1-28(61)39(25-60)56-48(68)41-27-71-70-26-40(57-43(63)34(51)21-30-13-5-3-6-14-30)47(67)54-37(22-31-15-7-4-8-16-31)45(65)55-38(23-32-24-52-35-18-10-9-17-33(32)35)46(66)53-36(19-11-12-20-50)44(64)59-42(29(2)62)49(69)58-41/h3-10,13-18,24,28-29,34,36-42,52,60-62H,11-12,19-23,25-27,50-51H2,1-2H3,(H,53,66)(H,54,67)(H,55,65)(H,56,68)(H,57,63)(H,58,69)(H,59,64)/t28-,29-,34-,36+,37+,38-,39-,40+,41+,42+/m1/s1

InChI key

DEQANNDTNATYII-OULOTJBUSA-N

Gene Information

human ... SSTR1(6751) , SSTR2(6752) , SSTR3(6753) , SSTR4(6754) , SSTR5(6755)

Looking for similar products? Visit Product Comparison Guide

Amino Acid Sequence

Phe-Cys-Phe-Trp-Lys-Thr-Cys-Thr-ol [Disulfide bridge: 2-7]

General description

Octreotide is a somatostatin analogue with D-Phe-Cys-Phe-D-Trp-Lys-ThrCys-Thr-OH amino acid sequence.

Biochem/physiol Actions

Octreotide is three times more potent than the native hormone in inhibiting the secretion of growth hormone glucagon and insulin in vivo. Octreotide regulates serum prolactin levels and resolves galactorrhea or (secondary) amenorrhea in acromegaly patients. Hence, this peptide can be considered as a potent therapeutic for acromegaly treatment.
Somatostatin analog that is 3-times more potent than the native hormone in inhibiting the secretion of growth hormone.

Other Notes

Lyophilized from 0.1% TFA in H2O

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Personal Protective Equipment

dust mask type N95 (US), Eyeshields, Gloves

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hendrik Bergsma et al.
Best practice & research. Clinical gastroenterology, 26(6), 867-881 (2013-04-16)
Peptide receptor radionuclide therapy (PRRT) with radiolabelled somatostatin analogues plays an increasing role in the treatment of patients with inoperable or metastasised gatroenteropancreatic neuroendocrine tumours (GEP-NETs). (90)Y-DOTATOC and (177)Lu-DOTATATE are the most used radiopeptides for PRRT with comparable tumour response
Rana Ben Azzouna et al.
Nuclear medicine communications, 38(1), 51-56 (2016-11-09)
The Ge/Ga generator is of increasing interest for clinical PET. The arrival on the market of the pharmaceutical-grade generator, which provides an eluate with chemical and radiochemical purities in conformity with the European Pharmacopeia specifications, makes the direct labelling of
Mattias Sandström et al.
Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 54(10), 1755-1759 (2013-08-10)
(68)Ga-DOTATOC and (68)Ga-DOTATATE are 2 radiolabeled somatostatin analogs for in vivo diagnosis of neuroendocrine tumors with PET. The aim of the present work was to measure their comparative biodistribution and radiation dosimetry. Ten patients diagnosed with neuroendocrine tumors were included.
Octreotide as primary therapy for acromegaly.
Newman CB
The Journal of Clinical Endocrinology and Metabolism, 83(9), 3034-3040 (1998)
Odaly Toffoletto et al.
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society, 30-31, 31-36 (2016-09-23)
To extend available dosing options in the treatment of growth hormone deficiency, a comparative pharmacokinetic and pharmacodynamic phase-1 clinical study involving subcutaneous administration of growth hormone was conducted. The test formulation (biosimilar recombinant human growth hormone; r-hGH; Somatotropin) and reference
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service